CIM
EW icon

Cambria Investment Management’s Edwards Lifesciences EW Stock Holding History

Cambria Investment Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$304K Buy
3,359
+76
+2% +$6.37K 0.02% 593
2026
Q1 		$263K Sell
3,283
-234
-7% -$19.3K 0.01% 555
2025
Q4 		$300K Buy
+3,517
New +$289K 0.02% 504
2024
Q3 		– Sell
-6,048
Closed -$559K – 357
2024
Q2 		$559K Buy
+6,048
New +$536K 0.03% 172

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Cambria Investment Management's EW Position: Q2 2026 in Review

Cambria Investment Management increased its Edwards Lifesciences (EW) stake by 2.3% in Q2 2026, buying an estimated $6.37K and bringing the position to 3,359 shares worth $304K. The position accounts for 0.02% of the portfolio, ranked #593.

Cambria Investment Management first reported a position in EW in Q2 2024 and has held it in 4 quarters since. The position peaked at $559K in Q2 2024. 1,328 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Cambria Investment Management held 3,359 shares of Edwards Lifesciences worth $304K as of Q2 2026.
  • Cambria Investment Management bought 76 Edwards Lifesciences shares in Q2 2026, an estimated $6.37K.
  • Edwards Lifesciences made up 0.02% of Cambria Investment Management's portfolio in Q2 2026, its #593 holding.
  • Cambria Investment Management first reported a position in Edwards Lifesciences in Q2 2024 and has held it in 4 quarters since.
  • Cambria Investment Management's Edwards Lifesciences position peaked at $559K in Q2 2024.
  • 1,328 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Cambria Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.